Medicamen Biotech Share Price & Earnings Call Analysis
- Market cap
- ₹369 Cr
- P/E
- 34.02
- ROE
- 3.95%
- PEG
- -2.54
- Price to sales
- 1.82
- Debt to equity
- 0.18
- 52W high / low
- ₹416 / ₹220
- Sales growth (5Y)
- 11.90%
- EBITDA margin
- 9.52%
- Net profit margin
- 4.96%
- Promoter holding
- 42.57%
- Sales (last year)
- ₹203 Cr
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Medicamen Biotec.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Medicamen Biotec
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Medicamen Biotec
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 37.15 | 40.50 | 42.67 | 44.20 | 45.01 | 41.48 | 42.84 | 41.14 | 26.00 | 38.45 | 42.23 | 43.49 | 54.68 |
| Expenses + | 30.38 | 33.09 | 36.51 | 38.61 | 38.18 | 36.62 | 36.29 | 34.90 | 27.10 | 34.42 | 37.18 | 38.41 | 50.56 |
| Operating Profit | 6.77 | 7.41 | 6.16 | 5.59 | 6.83 | 4.86 | 6.55 | 6.24 | -1.10 | 4.03 | 5.05 | 5.08 | 4.12 |
| OPM % | 18.22% | 18.30% | 14.44% | 12.65% | 15.17% | 11.72% | 15.29% | 15.17% | -4.23% | 10.48% | 11.96% | 11.68% | 7.53% |
| Other Income + | 0.35 | 0.38 | 0.55 | 0.83 | 0.54 | 0.58 | 0.29 | 0.14 | 5.22 | 0.47 | 0.37 | 0.53 | 1.73 |
| Interest | 0.86 | 0.96 | 0.91 | 0.65 | 1.87 | 0.68 | 1.01 | 0.73 | 0.62 | 0.56 | 0.84 | 0.78 | 0.60 |
| Depreciation | 1.61 | 1.68 | 1.80 | 1.76 | 1.77 | 1.74 | 2.57 | 2.17 | 0.47 | 1.77 | 1.81 | 1.75 | 1.73 |
| Profit before tax | 4.65 | 5.15 | 4.00 | 4.01 | 3.73 | 3.02 | 3.26 | 3.48 | 3.03 | 2.17 | 2.77 | 3.08 | 3.52 |
| Tax % | 13.12% | 14.37% | 24.75% | 31.17% | 16.62% | 25.17% | 30.06% | 27.59% | 20.79% | 24.42% | 20.22% | 15.58% | 15.62% |
| Net Profit + | 4.05 | 4.42 | 3.01 | 2.77 | 3.10 | 2.26 | 2.27 | 2.52 | 2.41 | 1.64 | 2.21 | 2.59 | 2.97 |
| EPS in Rs | 3.20 | 3.49 | 2.38 | 2.19 | 2.44 | 1.78 | 1.79 | 1.98 | 1.90 | 1.21 | 1.63 | 1.91 | 2.19 |
Financials of Medicamen Biotec
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 78 | 67 | 82 | 112 | 123 | 117 | 110 | 115 | 138 | 172 | 151 | 179 |
| Expenses + | 73 | 62 | 71 | 95 | 105 | 99 | 90 | 91 | 113 | 145 | 134 | 161 |
| Operating Profit | 5 | 6 | 12 | 17 | 17 | 18 | 20 | 24 | 25 | 27 | 17 | 18 |
| OPM % | 6% | 8% | 14% | 15% | 14% | 15% | 18% | 21% | 18% | 16% | 11% | 10% |
| Other Income + | 1 | 1 | 0 | 2 | 4 | 2 | 1 | 2 | 2 | 2 | 6 | 3 |
| Interest | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 6 | 4 | 3 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 7 | 7 | 7 |
| Profit before tax | 0 | 1 | 6 | 14 | 18 | 17 | 17 | 18 | 17 | 17 | 13 | 12 |
| Tax % | -267% | 32% | 19% | 27% | 31% | 26% | 25% | 18% | 13% | 21% | 26% | 19% |
| Net Profit + | 0 | 0 | 5 | 10 | 12 | 12 | 12 | 15 | 15 | 13 | 9 | 9 |
| EPS in Rs | 0.46 | 0.48 | 4.91 | 8.89 | 10.28 | 10.04 | 10.22 | 12.20 | 11.86 | 10.46 | 7.43 | 6.94 |
| Dividend Payout % | 0% | 0% | 0% | 12% | 10% | 5% | 10% | 8% | 8% | 10% | 13% | 14% |
Financials of Medicamen Biotec
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 |
| Reserves | 8 | 8 | 16 | 63 | 75 | 110 | 122 | 136 | 181 | 196 | 205 | 266 |
| Borrowings + | 21 | 19 | 18 | 14 | 12 | 11 | 19 | 26 | 26 | 30 | 27 | 37 |
| Other Liabilities + | 31 | 23 | 29 | 28 | 38 | 43 | 39 | 52 | 57 | 55 | 48 | 45 |
| Total Liabilities | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 294 | 293 | 362 |
| Fixed Assets + | 20 | 19 | 19 | 25 | 24 | 34 | 90 | 92 | 92 | 91 | 86 | 84 |
| CWIP | 0 | 0 | 0 | 0 | 15 | 40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 8 | 8 | 8 |
| Other Assets + | 49 | 41 | 54 | 92 | 97 | 100 | 101 | 131 | 180 | 195 | 199 | 270 |
| Total Assets | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 226 | 277 | 294 | 293 | 362 |
Financials of Medicamen Biotec
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -3 | 6 | 4 | -5 | 4 | 12 | 13 | 5 | -4 | -0 | -3 | |
| Cash from Investing Activity + | 0 | -1 | -2 | -8 | -15 | -39 | -18 | -8 | -8 | -9 | -2 | |
| Cash from Financing Activity + | 3 | -5 | -1 | 33 | -4 | 21 | 6 | 4 | 28 | 3 | -7 | |
| Net Cash Flow | -0 | 0 | 0 | 20 | -14 | -6 | 1 | 1 | 17 | -6 | -11 | |
| Free Cash Flow | -3 | 5 | 1 | -14 | -11 | -26 | -5 | -4 | -10 | -6 | -5 | |
| CFO/OP | -65% | 112% | 31% | -29% | 48% | 88% | 87% | 33% | -27% | 10% | -7% |
Financials of Medicamen Biotec
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 124 | 87 | 114 | 126 | 129 | 137 | 165 | 193 | 159 | 102 | 141 | 132 |
| Inventory Days | 95 | 95 | 102 | 77 | 67 | 85 | 28 | 188 | 230 | 237 | 274 | 258 |
| Days Payable | 187 | 160 | 165 | 118 | 134 | 160 | 161 | 291 | 232 | 152 | 182 | 138 |
| Cash Conversion Cycle | 32 | 22 | 51 | 85 | 62 | 62 | 32 | 91 | 157 | 188 | 234 | 252 |
| Working Capital Days | 7 | 3 | 34 | 89 | 116 | 139 | 130 | 146 | 151 | 117 | 186 | 197 |
| ROCE % | 12% | 12% | 24% | 25% | 20% | 15% | 13% | 12% | 11% | 10% | 7% | 5% |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.